PACTR2010020001771828
Completed
未知
Safety and Immunogenicity of Heterologous Prime-Boost with the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME- TRAP in Healthy Adults in a Malaria Endemic Area
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Malaria
- Sponsor
- niversity of Oxford
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •·Consenting adult males aged 18\-50 years in good health.
- •·Will remain resident in the study area for the study duration
Exclusion Criteria
- •·Clinically significant history of the following conditions; skin disorder (eczema, etc.), allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness.
- •·History of splenectomy
- •·Haemoglobin less than 9\.0 g/dl
- •·Clinically significant abnormalities of laboratory screening tests (full blood count, ALT, creatinine levels, urine dipstick examination for blood and protein).
- •·Blood transfusion within one month of the beginning of the study
- •·History of vaccination with previous experimental malaria vaccines
- •·Administration of any other vaccine or immunoglobulin within two weeks before vaccination.
- •·Current participation in another clinical trial, or within 12 weeks of this study
- •·Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial.
- •·Likelihood of travel away from the study area
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Immunogenicity and safety of heterologous prime boost COVID-19 vaccines in ThailandThe immune response after heterologous COVID-19 vaccine administration in healthy volunteers.COVID-19 vaccine, heterologous prime-boost, ChAdOx1, coronavac, Sinovac.TCTR20210714003Chulabhorn Royal Academy264
Completed
Not Applicable
Safety of Malaria vaccines in Gambian infantsMalariaPaediatricsPACTR201401000363170niversity of Oxford36
Completed
Not Applicable
Safety of Malaria vaccines in Gambian childreMalariaPaediatricsPACTR201204000362870niversity of Oxford36
Unknown
Not Applicable
Safety of Malaria vaccines in Gambian adults , children and infantsMalariaPACTR201008000221638Oxford University, Jenner Institute52
Recruiting
Phase 4
Safety and Immunogenicity of heterologous or homologous booster after complete vaccination against COVID-19.Covid19D012141RBR-5y9y7p7Secretaria Municipal de Saúde do Rio de Janeiro